125 related articles for article (PubMed ID: 18438427)
1. An antibody inhibitor of the LMO2-protein complex blocks its normal and tumorigenic functions.
Nam CH; Lobato MN; Appert A; Drynan LF; Tanaka T; Rabbitts TH
Oncogene; 2008 Aug; 27(36):4962-8. PubMed ID: 18438427
[TBL] [Abstract][Full Text] [Related]
2. Targeting LMO2 with a peptide aptamer establishes a necessary function in overt T-cell neoplasia.
Appert A; Nam CH; Lobato N; Priego E; Miguel RN; Blundell T; Drynan L; Sewell H; Tanaka T; Rabbitts T
Cancer Res; 2009 Jun; 69(11):4784-90. PubMed ID: 19487290
[TBL] [Abstract][Full Text] [Related]
3. The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis.
Yamada Y; Warren AJ; Dobson C; Forster A; Pannell R; Rabbitts TH
Proc Natl Acad Sci U S A; 1998 Mar; 95(7):3890-5. PubMed ID: 9520463
[TBL] [Abstract][Full Text] [Related]
4. A DNA-binding mutant of TAL1 cooperates with LMO2 to cause T cell leukemia in mice.
Draheim KM; Hermance N; Yang Y; Arous E; Calvo J; Kelliher MA
Oncogene; 2011 Mar; 30(10):1252-60. PubMed ID: 21057528
[TBL] [Abstract][Full Text] [Related]
5. The LMO2 T-cell oncogene is activated via chromosomal translocations or retroviral insertion during gene therapy but has no mandatory role in normal T-cell development.
McCormack MP; Forster A; Drynan L; Pannell R; Rabbitts TH
Mol Cell Biol; 2003 Dec; 23(24):9003-13. PubMed ID: 14645513
[TBL] [Abstract][Full Text] [Related]
6. A previously unrecognized promoter of LMO2 forms part of a transcriptional regulatory circuit mediating LMO2 expression in a subset of T-acute lymphoblastic leukaemia patients.
Oram SH; Thoms JA; Pridans C; Janes ME; Kinston SJ; Anand S; Landry JR; Lock RB; Jayaraman PS; Huntly BJ; Pimanda JE; Göttgens B
Oncogene; 2010 Oct; 29(43):5796-808. PubMed ID: 20676125
[TBL] [Abstract][Full Text] [Related]
7. Structure of the leukemia oncogene LMO2: implications for the assembly of a hematopoietic transcription factor complex.
El Omari K; Hoosdally SJ; Tuladhar K; Karia D; Vyas P; Patient R; Porcher C; Mancini EJ
Blood; 2011 Feb; 117(7):2146-56. PubMed ID: 21076045
[TBL] [Abstract][Full Text] [Related]
8. Chromosomal translocations and leukaemia: a role for LMO2 in T cell acute leukaemia, in transcription and in erythropoiesis.
Rabbitts TH; Axelson H; Forster A; Grutz G; Lavenir I; Larson R; Osada H; Valge-Archer V; Wadman I; Warren A
Leukemia; 1997 Apr; 11 Suppl 3():271-2. PubMed ID: 9209362
[TBL] [Abstract][Full Text] [Related]
9. Functional interactions between Lmo2, the Arf tumor suppressor, and Notch1 in murine T-cell malignancies.
Treanor LM; Volanakis EJ; Zhou S; Lu T; Sherr CJ; Sorrentino BP
Blood; 2011 May; 117(20):5453-62. PubMed ID: 21427293
[TBL] [Abstract][Full Text] [Related]
10. The role of LMO2 in development and in T cell leukemia after chromosomal translocation or retroviral insertion.
Nam CH; Rabbitts TH
Mol Ther; 2006 Jan; 13(1):15-25. PubMed ID: 16260184
[TBL] [Abstract][Full Text] [Related]
11. A novel transcript of the LMO2 gene, LMO2-c, is regulated by GATA-1 and PU.1 and encodes an antagonist of LMO2.
Wang Q; Zhang M; Wang X; Yuan W; Chen D; Royer-Pokora B; Zhu T
Leukemia; 2007 May; 21(5):1015-25. PubMed ID: 17361224
[TBL] [Abstract][Full Text] [Related]
12. Single domain intracellular antibodies from diverse libraries: emphasizing dual functions of LMO2 protein interactions using a single VH domain.
Tanaka T; Sewell H; Waters S; Phillips SE; Rabbitts TH
J Biol Chem; 2011 Feb; 286(5):3707-16. PubMed ID: 20980262
[TBL] [Abstract][Full Text] [Related]
13. Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy.
Pike-Overzet K; de Ridder D; Weerkamp F; Baert MR; Verstegen MM; Brugman MH; Howe SJ; Reinders MJ; Thrasher AJ; Wagemaker G; van Dongen JJ; Staal FJ
Leukemia; 2007 Apr; 21(4):754-63. PubMed ID: 17268520
[TBL] [Abstract][Full Text] [Related]
14. LMO2 at 25 years: a paradigm of chromosomal translocation proteins.
Chambers J; Rabbitts TH
Open Biol; 2015 Jun; 5(6):150062. PubMed ID: 26108219
[TBL] [Abstract][Full Text] [Related]
15. LIM-only protein Lmo2 forms a protein complex with erythroid transcription factor GATA-1.
Osada H; Grutz GG; Axelson H; Forster A; Rabbitts TH
Leukemia; 1997 Apr; 11 Suppl 3():307-12. PubMed ID: 9209374
[TBL] [Abstract][Full Text] [Related]
16. Identification of the key LMO2-binding determinants on Ldb1.
Ryan DP; Sunde M; Kwan AH; Marianayagam NJ; Nancarrow AL; Vanden Hoven RN; Thompson LS; Baca M; Mackay JP; Visvader JE; Matthews JM
J Mol Biol; 2006 May; 359(1):66-75. PubMed ID: 16616188
[TBL] [Abstract][Full Text] [Related]
17. Competitive SPR using an intracellular anti-LMO2 antibody identifies novel LMO2-interacting compounds.
Canning P; Bataille C; Bery N; Milhas S; Hayes A; Raynaud F; Miller A; Rabbitts T
J Immunol Methods; 2021 Jul; 494():113051. PubMed ID: 33794223
[TBL] [Abstract][Full Text] [Related]
18. The oncogenic LIM-only transcription factor Lmo2 regulates angiogenesis but not vasculogenesis in mice.
Yamada Y; Pannell R; Forster A; Rabbitts TH
Proc Natl Acad Sci U S A; 2000 Jan; 97(1):320-4. PubMed ID: 10618416
[TBL] [Abstract][Full Text] [Related]
19. Conformational flexibility of the oncogenic protein LMO2 primes the formation of the multi-protein transcription complex.
Sewell H; Tanaka T; El Omari K; Mancini EJ; Cruz A; Fernandez-Fuentes N; Chambers J; Rabbitts TH
Sci Rep; 2014 Jan; 4():3643. PubMed ID: 24407558
[TBL] [Abstract][Full Text] [Related]
20. Expression of the leukemia oncogene Lmo2 is controlled by an array of tissue-specific elements dispersed over 100 kb and bound by Tal1/Lmo2, Ets, and Gata factors.
Landry JR; Bonadies N; Kinston S; Knezevic K; Wilson NK; Oram SH; Janes M; Piltz S; Hammett M; Carter J; Hamilton T; Donaldson IJ; Lacaud G; Frampton J; Follows G; Kouskoff V; Göttgens B
Blood; 2009 Jun; 113(23):5783-92. PubMed ID: 19171877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
